Layla Parast

May 29, 2024 | onlinelibrary.wiley.com | Layla Parast |Lu Tian |Tianxi Cai

Supporting Information Filename Description sim10122-sup-0001-Supinfo.zipZip archive, 50.9 KB Data S1: Supporting Information. REFERENCES 1. Are surrogate markers adequate to assess cardiovascular disease drugs? Jama. 1999; 282(8): 790-795. 2 FDA. Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure. https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure 2022. 3 Geary.

Dec 11, 2023 | onlinelibrary.wiley.com | Yunshan Duan |Layla Parast

REFERENCES 1. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 1989; 8: 431-440. 2, , . Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992; 11: 167-178. 3, . A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics. 2002; 58: 803-812. 4, , . Robust estimation of the proportion of treatment effect explained by surrogate marker information. Stat Med. 2016; 35: 1637-1653. 5, .

Oct 31, 2023 | drc.bmj.com | Layla Parast |Lu Tian |Tianxi Cai |Latha Palaniappan

DiscussionThe results demonstrate that, of the five examined surrogate markers, fasting glucose and HOMA-IR explained the largest proportions of the treatment effect when comparing lifestyle intervention with placebo. The TyG index and HbA1c were the weakest surrogate markers in terms of the proportion of the treatment effect that could be explained.